Aktienanalyse zu Adaptive Biotechnologies Corporation (ADPT)ADPTAdaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Adaptive Biotechnologies Corp is a good buy right now due to its recent revenue growth of 22% year-over-year, reaching $71.6 million, and a strong gross margin of 71.23%. Despite a recent wider net loss of $39.94 million, the company has raised its full-year revenue guidance for its Minimal Residual Disease (MRD) business, which is expected to generate between $268 million and $278 million. The main risk is the high debt to equity ratio of 222.27%, which indicates significant leverage.